placeholder image
ECOG-ACRIN 1512 Investigators All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 
    Lancet Oncology. 2016
    • Contact
    full name
  • ECOG-ACRIN 1512 Investigators
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration